fat loss rather than diminution in non-fat body mass as indicated by different means: impedance measure-ments, waist, hip and thigh measurements, and sub-cutaneous fat measurements. Earlier, Udani et al. [20] reported reduced body weights and serum triglyc-erides in 14 obese adults receiving 1500 mg[r]
exclude opportunistic brain infection, however of the eight lumbar punctures that were performed, no op-portunistic infections were found. Similarly, even though HIV-1-infected subjects had advanced immu-nosuppression, there were no individuals who had any history of any opportunistic infections, in[r]
University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550 Japan. Tel: +81-52-744-2133, Fax: +81-52-744-2971, e-mail: y-goto@med.nagoya-u.ac.jp Received: 2006.09.22; Accepted: 2006.10.25; Published: 2006.11.01 Background: Various single nucleotide polymorphisms (SNPs) have ex[r]
A group of 16 females, aged 80-93 years old, was divided into 2 groups according to their baseline DHEA-S lev-els: Lower Halves (N = 8) and Upper Halves (N = 8), and participated in a 4-month exercise intervention trial. Insulin response with an oral glucose tolerance test (OGTT), chol[r]
Exon 1 (transcript variant 3) and exon 10 were amplified from selected samples with PCR parameters as described above. After a control electrophoresis on 2% agarose gels, the PCR products were directly subjected to processing with Surveyor nuclease [13] (Transgenomic, Omaha, USA) according to[r]
pattern. It is possible that participants who have been diagnosed with a chronic disease may have changed their diet. To address this concern we adjusted for the presence of chronic disease (CHD, cancer, and stroke) and hypertension throughout the analyses. We also repeated the analyses exclu[r]
acceptable participation rate as well as less selection bias. We have chosen to report from the youngest age cohort participating in “The Prospective Population Study of Women in Gothenburg” as this was the age group in which lung function status was most thoroughly examined and selection bias due t[r]
As an example we presented the finding that maternal use of loratadine in early pregnancy was associated with a roughly doubled risk for infant hypospadias. We concluded: “The finding can still be random, but causality cannot be dismissed, even though the mechanism of action is not understood[r]
respective Rice-fluid) physiological saline solution, respectively. The cultures were incubated with gentle shaking at 37°C in a microaerophilic atmosphere. Samples (100μl) for viability measurement were taken at various points of time, that is, 30min., 60min., and 120min., respectively. Viab[r]
was very large. Our original hypothesis was that this would be the case if flavanol-rich cocoa and its influ-ence on nitric oxide synthesis had implications for disease pathogenesis, as has been suggested [26]. We could explain this extraordinary difference in the risk of death by proposing either <[r]
new urate oxidase. [12] In fact, the old and the new urate oxidase do not significantly differ from a pharmacodynamic point of view; the only difference consists in the reduction of rasburicase’s adverse effects. Studies have reported the presence of antibodies antirasburicase in some pa-tien[r]
been deleted have been developed [34, 45]. This modification reportedly has reduced toxicity and prolonged gene expression in some experiments [5, 33]. Nevertheless, we constructed a recombinant BMP9 helper-dependent adenoviral vector and found that the osteogenic potentials of this vector we[r]
genotypes 2 and 3 and 48 weeks in genotype 1 infection. Hematologic inclusion criteria included ANC > 800 cells/mL, hemoglobin > 10 g/dL and platelets > 35,000/mL. Growth factors were allowed in the management of therapy-induced cytopenias. The investigators estimated that “one[r]
non-responders to peginterferon alpha 2b and ribavirin. In: AASLD (Abstract 413); Oct 29- Nov 2 2004; Boston, MA. 36. Gross JB et al. Renew Trial- High dose re-treatment with peginterferon alpha 2b plus ribavirin for non responders in chronic HCV patients. In: AASLD 2003 (Abstract 321); Oct 24-28 20[r]